Long-Term Follow-Up of Long-Acting Cabotegravir for HIV Pre-Exposure Prophylaxis in Participants from HPTN 083 and HPTN 084 Studies

What this Trial Is About

This research aims to evaluate the long-term use of long-acting injectable cabotegravir (CAB LA) for preventing HIV infection in participants who have completed previous related studies (HPTN 083 and HPTN 084) sponsored by the Division of AIDS. The study focuses on those at risk for HIV and monitors new HIV infections, serious adverse events, and injection site reactions over an extended period. Participants in this study will continue receiving CAB LA at a dose of 600 mg administered by gluteal intramuscular injections every eight weeks. All enrolled individuals have previously received CAB LA in the parent studies or their sub-studies and will maintain this treatment schedule throughout the study period. During the study, participants will be regularly monitored for new HIV infections, serious adverse events, and any adverse reactions related to the injections or treatment that could lead to withdrawal. Follow-up will occur for up to approximately three years, with researchers collecting clinical and laboratory data to assess safety and effectiveness. Participants will have ongoing access to CAB LA under medical supervision during this long-term follow-up period.

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)